Skip to main content
Fig. 2 | Alzheimer's Research & Therapy

Fig. 2

From: Preclinical and first-in-human evaluation of AL002, a novel TREM2 agonistic antibody for Alzheimer’s disease

Fig. 2

Pharmacokinetics of repeat-dose AL002 in cynomolgus monkeys. (A) Mean + SD serum concentrations of AL002. For Days 1 to 22, n = 6 in 20 mg/kg and 80 mg/kg, n = 10 in 250 mg/kg. For Day 29, n = 4 in the 250 mg/kg group. (B) Mean ± SEM CSF concentration of AL002. LLOQ standard was 5.0 ng/mL. n = 6 in 20 mg/kg and 80 mg/kg, n = 10 in 250 mg/kg. Black arrows indicate time of dosing. CSF, cerebrospinal fluid; h, hours; LLOQ, lower limit of quantification; SD, standard deviation

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193